Drugs / Rapidly generated virus specific T (R-MVST) cells
Rapidly generated virus specific T (R-MVST) cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06926894 | Apr 2025 → Apr 2029 expected | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection, immunodeficiency disease +1 | Columbia University | Recruiting | No outcome recorded |
| Phase 1 | NCT05183490 | May 2022 → Jun 2028 expected | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection, polyomavirus infectious disease | Columbia University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rapidly generated virus specific T (R-MVST) cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05183490 ↗ |
| Modality | Cell therapy | “The cell product is called rapidly generated virus specific T cells or R-MVST.” NCT05183490 ↗ |